What is the price-to-earnings ratio of Neuropace?
The price-earnings ratio of Neuropace is currently -10.55.
Neuropace P/E 2025
Neuropace P/E
-10.55
Ticker
NPCE
ISIN
US6412881053
As of Aug 15, 2025, Neuropace's P/E ratio was -10.55, a -12.16% change from the -12.01 P/E ratio recorded in the previous year.
The Neuropace P/E history
Neuropace Aktienanalyse
What does Neuropace do?
Neuropace Inc is a US-based company specializing in the development and manufacturing of medical devices. It is headquartered in Mountain View, California and has been operating since 2000. The company was founded as a spin-off from a study conducted by Dr. Martha Morrell at Stanford University, focusing on the treatment of epilepsy with implanted devices. Neuropace Inc's business model involves manufacturing and marketing medical devices for epilepsy treatment. These devices, known as neurostimulators, are implantable devices that send electrical impulses to the brain and can reduce epileptic seizures. The company has been involved in various areas of epilepsy treatment, including the development of devices for patients with pharmacoresistant focal epilepsies. These devices can be implanted in patients who do not respond to traditional treatments such as medications or surgeries. Neuropace Inc has also started focusing on the development of devices for epilepsy diagnosis. One of these devices is the ambulatory EEG monitor, which records brain activity and allows doctors to better detect epilepsy seizures. The company has launched a range of products to achieve its goal of enabling patients to have a better quality of life. The key product is the RNS neurostimulator, which is implanted in patients and continuously monitors brain activity using electrodes placed in the brain to monitor brain waves. When the neurostimulator detects unusual activity, it automatically sends impulses to the brain to prevent or reduce the occurrence of epileptic seizures. The benefit is that patients experience fewer seizures and can better organize and plan their daily lives. Neuropace Inc has a competitive position in the market with its products for treating pharmacoresistant focal epilepsies. The RNS neurostimulator is the only device approved by the US Food and Drug Administration FDA capable of reducing critical neurological outcomes in epilepsy. The company also has a strong presence in the field of epilepsy diagnosis, particularly with the ambulatory EEG monitor. Neuropace Inc has also formed strategic partnerships with other companies to bring its technologies to the market. The company has formed alliances with Medtronic, among others, for the marketing and distribution of the RNS neurostimulator. Through these partnerships, Neuropace Inc has expanded its reach in the market and strengthened its relationships with leading companies in the industry. In summary, Neuropace Inc is a company specializing in the development and manufacturing of medical devices for epilepsy treatment. The company has expanded its technologies to cover a broader range of epilepsy conditions and has achieved a high level of success with its products. With solid partnerships and a strong commitment to epilepsy treatment, Neuropace Inc is expected to continue leading the market for medical devices. Neuropace ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Neuropace's P/E Ratio
The Price to Earnings (P/E) Ratio of Neuropace is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Neuropace's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Neuropace is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Neuropace’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Neuropace stock
How has the price-earnings ratio of Neuropace changed compared to last year?
The price-to-earnings ratio of Neuropace has increased by -12.16% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Neuropace high compared to other companies?
Yes, the price-to-earnings ratio of Neuropace is high compared to other companies.
How does an increase in the price-earnings ratio of Neuropace affect the company?
An increase in the price-earnings ratio of Neuropace would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Neuropace affect the company?
A decrease in the price-earnings ratio of Neuropace would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Neuropace?
Some factors that influence the price-earnings ratio of Neuropace are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Neuropace pay?
Over the past 12 months, Neuropace paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neuropace is expected to pay a dividend of 0 USD.
What is the dividend yield of Neuropace?
The current dividend yield of Neuropace is .
When does Neuropace pay dividends?
Neuropace pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Neuropace?
Neuropace paid dividends every year for the past 0 years.
What is the dividend of Neuropace?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Neuropace located?
Neuropace is assigned to the 'Health' sector.
Wann musste ich die Aktien von Neuropace kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Neuropace from 8/15/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/15/2025.
When did Neuropace pay the last dividend?
The last dividend was paid out on 8/15/2025.
What was the dividend of Neuropace in the year 2024?
In the year 2024, Neuropace distributed 0 USD as dividends.
In which currency does Neuropace pay out the dividend?
The dividends of Neuropace are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Neuropace
Our stock analysis for Neuropace Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuropace Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.